Effect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study

What Was Tested

This randomized controlled trial paper looks at Tirzepatide.

The researchers evaluated the impact of tirzepatide on health-related quality of life (HR-QoL) in Japanese individuals with obesity disease from the phase 3 SURMOUNT-J trial.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Tirzepatide.

The comparison arm used a placebo, so changes seen with Tirzepatide could be set against what happens without it.

Prespecified analyses assessed changes from baseline to Week 72 in HR-QoL using the Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) and 36-Item Short-Form Health Survey Version 2.0 (SF-36v2), and assessed subgroup differences by sex (male, female), baseline body mass index (< 35, ≥ 35 kg/m2) and age (< 65, ≥ 65 years).

Post hoc analyses examined correlations between HR-QoL scores and percentage weight loss.

What Was Measured

PubMed files the paper under topics including Tirzepatide, Quality of Life, Obesity, Japan, Patient Reported Outcome Measures, Weight Loss and Anti-Obesity Agents.

Author keywords: GLP‐1, clinical trial, obesity therapy and patient reported outcomes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Tirzepatide compound page, all human trials.